Moreover, an FDA‐approved drug, digitoxin, was evaluated and confirmed to directly bind to PD2 and disturb the PD2/39A_S/MYC circuit to effectively prevent HCC tumorigenesis. This evidence concerns the gene PAF1 and hepatocellular carcinoma.